- Conditions
- Healthy Volunteer
- Interventions
- Denosumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 65 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 7,031
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers, Dengue, Human Challenge Trial
- Interventions
- rDEN2delta30-7169
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- IV racemic methadone HCl, Oral racemic methadone HCl
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy
- Interventions
- ACU-4429, matching placebo tablet
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
- Interventions
- EDP-978, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- ABX-002
- Drug
- Lead sponsor
- Autobahn Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy
- Interventions
- Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy Volunteers
- Interventions
- TAK-418, [18F]MNI-1054 (radiotracer)
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parkinson Disease, Gaucher Disease
- Interventions
- 15-0 H20
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Platelet Aggregation
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Drug Safety
- Interventions
- Placebo, VIA-3196
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Chronic Pain, Lower Back Pain Chronic
- Interventions
- PNS Injectrode F1
- Device
- Lead sponsor
- Neuronoff, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- SL-325, Placebo (Normal Saline)
- Biological · Other
- Lead sponsor
- Shattuck Labs, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy
- Interventions
- Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Healthy Males
- Interventions
- Naloxone, IV Methylnaltrexone (MNTX), Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Healthy Volunteer
- Interventions
- GDC-0853, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy Participants, Young Healthy Adults, Elderly (People Aged 65 or More)
- Interventions
- Not listed
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- REGN10933+REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
- Conditions
- Peripheral Intavenous Catheter Stabilization
- Interventions
- Securis™ Stabilization Device
- Device
- Lead sponsor
- Becton, Dickinson and Company
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Obesity
- Interventions
- K-757, K-757 and open-label sitagliptin, Matching placebo to K-757, Matching placebo to K-757 and matching placebo to K-833, K-757 and K-833, Matching placebo to K-757, open-label sitagliptin
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy Subjects
- Interventions
- Not listed
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Healthy Volunteers
- Interventions
- dapsone gel, dapsone gel vehicle
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Healthy, Renal Insufficiency
- Interventions
- LY3437943
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Tustin, California • Miami, Florida • Orlando, Florida + 1 more